Clinical Trial Update: A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

IGM Biosciences' Phase 1b trial of Imvotamab in moderate-to-severe rheumatoid arthritis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Imvotamab (imvotamab)

Snippet

Sponsor: IGM Biosciences, Inc. | Conditions: Rheumatoid Arthritis, Arthritis, Rheumatoid | Phase 1 | Status: TERMINATED